检索结果 - Björn Nashan

Refine Results
  1. 1
    Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation

    Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation 由 Björn Nashan, Franco Citterio

    出版 2012
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence

    The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence 由 Göran B. Klintmalm, Björn Nashan

    出版 2014
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    Everolimus and sirolimus in transplantation-related but different

    Everolimus and sirolimus in transplantation-related but different 由 Jost Klawitter, Björn Nashan, Uwe Christians

    出版 2015
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    Clinical validation studies of neoral C2 monitoring: a review

    Clinical validation studies of neoral C2 monitoring: a review 由 Björn Nashan, Edward Cole, Gary Levy, Éric Thervet

    出版 2002
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  5. 5
    The Diagnosis and Treatment of Cholangiocarcinoma

    The Diagnosis and Treatment of Cholangiocarcinoma 由 Arndt Vogel, Henning Wege, Karel Caca, Björn Nashan, Ulf P. Neumann

    出版 2014
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  6. 6
    REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1

    REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1 由 Björn Nashan, Susan Light, Ian R. Hardie, Amy Lin, J. R. Johnson

    出版 1999
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study

    Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study 由 Björn Nashan, John J. Curtis, Claudio Ponticelli, Georges Mourad, Jonathan S. Jaffe, T Haas

    出版 2004
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption

    Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption 由 Katharina Staufer, Hilke Andresen, Eik Vettorazzi, Niels Tobias, Björn Nashan, Martina Sterneck

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

    Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells 由 Nicole Grabinski, Florian Ewald, Bianca T. Hofmann, Katharina Staufer, Udo Schumacher, Björn Nashan, Manfred Jücker

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Presence of EpCAM‐positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma

    Presence of EpCAM‐positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma 由 Kornelius Schulze, Christin Gasch, Katharina Staufer, Björn Nashan, Ansgar W. Lohse, Klaus Pantel, Sabine Riethdorf, Henning Wege

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Primary human hepatocytes on biodegradable poly(l-lactic acid) matrices: A promising model for improving transplantation efficiency with tissue engineering

    Primary human hepatocytes on biodegradable poly(l-lactic acid) matrices: A promising model for improving transplantation efficiency with tissue engineering 由 É Török, Marc Lütgehetmann, Jeanette Bierwolf, Stefan Melbeck, J. Düllmann, Björn Nashan, X. Peter, Joerg M. Pollok

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    PERSISTENCE OF DONOR LYMPHOCYTES IN LIVER ALLOGRAFT RECIPIENTS

    PERSISTENCE OF DONOR LYMPHOCYTES IN LIVER ALLOGRAFT RECIPIENTS 由 Hans J. Schlitt, HIROMICHI KANEHIRO, Gereon Raddatz, Gustav Steinhoff, NICOLAS RICHTER, Björn Nashan, B. Ringe, K Wonigeit, R. Pichlmayr

    出版 1993
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Acute liver failure induced by green tea extracts: Case report and review of the literature

    Acute liver failure induced by green tea extracts: Case report and review of the literature 由 Michele Molinari, Kymberly D. Watt, Tomasz Kruszyna, Rebecca A. Nelson, Mark Walsh, Weei-Yuan Huang, Björn Nashan, Kevork Peltekian

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Recurrent Immunoglobulin A Nephropathy After Renal Transplantation

    Recurrent Immunoglobulin A Nephropathy After Renal Transplantation 由 Christine Ohmacht, Volker Kliem, Michael Burg, Björn Nashan, Hans-J rgen Schlitt, R. Brunkhorst, Karl‐Martin Koch, J. Floege

    出版 1997
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events

    Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events 由 Marie Laryea, Kymberly D. Watt, Michele Molinari, Mark Walsh, Vivian C. McAlister, Paul J. Marotta, Björn Nashan, Kevork Peltekian

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection

    Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection 由 Johann von Felden, Kornelius Schulze, Till Krech, Florian Ewald, Björn Nashan, Klaus Pantel, Ansgar W. Lohse, Sabine Riethdorf, Henning Wege

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    RESULTS OF 3-YEAR PHASE III CLINICAL TRIALS WITH DACLIZUMAB PROPHYLAXIS FOR PREVENTION OF ACUTE REJECTION AFTER RENAL TRANSPLANTATION1

    RESULTS OF 3-YEAR PHASE III CLINICAL TRIALS WITH DACLIZUMAB PROPHYLAXIS FOR PREVENTION OF ACUTE REJECTION AFTER RENAL TRANSPLANTATION1 由 Ginny L. Bumgardner, Ian R. Hardie, Robert W. Johnson, Amy Lin, Björn Nashan, Mark D. Pescovitz, Eleanor L. Ramos, Flavio Vincenti

    出版 2001
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Ki67, E-CADHERIN, AND p53 AS PROGNOSTIC INDICATORS OF LONG-TERM OUTCOME AFTER LIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE TUMORS

    Ki67, E-CADHERIN, AND p53 AS PROGNOSTIC INDICATORS OF LONG-TERM OUTCOME AFTER LIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE TUMORS 由 Jens Rosenau, Mathias Bähr, Reinhard von Wasielewski, Michael Mengel, Hartmut Schmidt, Björn Nashan, Hauke Lang, J. Klempnauer, Michael P. Manns, Klaus Boeker

    出版 2002
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Transplantation Procedures in Children With Primary Hyperoxaluria Type 1: Outcome and Longitudinal Growth

    Transplantation Procedures in Children With Primary Hyperoxaluria Type 1: Outcome and Longitudinal Growth 由 Florian Brinkert, Rainer Ganschow, K. Helmke, Egmond Harps, Lutz Fischer, Björn Nashan, Bernd Höppe, Stephanie Kulke, Dirk E. Müller‐Wiefel, Markus J. Kemper

    出版 2009
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation

    Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation 由 Enke Grabhorn, Thomas M.C. Binder, Denise Obrecht, Florian Brinkert, A. Lehnhardt, Uta Herden, Sven Peine, Björn Nashan, Rainer Ganschow, Andrea Briem‐Richter

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: